

Attorney Docket No.: JIJ-P06-504

In the claims:

Please cancel claim 91 without prejudice.

For the convenience of the Examiner, all pending claims, whether or not amended, are presented below.

97. (Reiterated) A method for decreasing neuronal cell death associated with a neuropathy, comprising contacting said neuronal cell with a morphogen selected from the group consisting of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and BMP6, wherein the morphogen stimulates the production of an N-CAM or L1 isoform in said neuronal cell.
99. (Reiterated) A method for decreasing neuronal cell death associated with a chemical or physical injury, comprising contacting said neuronal cell with a morphogen selected from the group consisting of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vgl, Vgr-1, BMP3, BMP5, and BMP6, wherein the morphogen stimulates the production of an N-CAM or L1 isoform in said neuronal cell.
- 
105. (Amended) The method of claim 97 or 99, wherein the morphogen is human OP-1.
106. (Amended) The method of claim 97 or 99, wherein the morphogen is mouse OP-1.
- 52 107. (Amended) The method of claim 97 or 99, wherein the morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, BMP2A, BMP2B, Vgl, Vgr-1, BMP5, or BMP6.
108. (Amended) The method of claim 97 or 99, wherein the morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, BMP5, or BMP6.
- 

*The claims presented above incorporate changes as indicated by the marked-up versions below.*

105. (Amended) The method of claim ~~91~~, 97 or 99, wherein the morphogen is human OP-1.
106. (Amended) The method of claim ~~91~~, 97 or 99, wherein the morphogen is mouse OP-1.
107. (Amended) The method of claim ~~91~~, 97 or 99, wherein the morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, BMP2A, BMP2B, Vgl, Vgr-1, BMP5, and or BMP6.